Abstract
The application of melanoma-derived gp50 was more effective in mice with i.c. transplanted melanoma B16; however, mice with s.c. transplanted tumors demonstrated an insignificant increase in survival. Spleen mononuclear cells obtained from i.c. B16 transplanted mice showed enhanced cytotoxic activity after the third injection of gp50, while histological examination of brain tissue specimens obtained in gp50-vaccinated mice after i.c. B16 cell challenge demonstrated a quantitative increase of tumor-infiltrating mononuclear cells. The results provided the evidence that gp50 can be effective for melanoma treatment.
References
1. Filchakov F. V. et al.: Mikroskopicheskiy variant metoda opredeleniya cytotoxicheskoy activnosti limfocytov. Lab. Diagnostika, 1, 28, 1998.
2. Kim C. J.: Immunotherapy for melanoma. Cancer Control, 1, 22, 2002.
3. Liu Y. et al.: Time course analysis and modulating effects of established brain tumor on activespecific immunotherapy. Neurosurg Focus, 6, e3, 2000.
4. Mansour M.: Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/helper peptides in VacciMax®. J. Transl. Med., 5, 20, 2007.
5. Marchett i D.: Brain-metastatic melanoma: a neurotrophic perspective. Pathol. Oncol. Res., 9, 147, 2003.
6. Sampson J. H. et al.: Subcutaneous vaccination with irradiated, cytokine-producing tumor cellsstimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. PNAS, 93, 10399, 1996.
7. Shlyakhovenko V. O. et al.: Protypuchlynna autovaccina na osnovi glikopeptydiv puchlynnych klityn. Onkologiya, 6, 180, 2004.
8. Terando A. M. et al.: Vaccine therapy for melanoma: current status and future directions. Vaccine, 25, 4, 2007.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2009 Authors